With the Nike Mind 001 and 002, Nike is now in the neuroscience game. Its first foray into “mind altering” footwear comes by way of a pair of mules (the Mind 001) and a matching sneaker (the Mind 002) ...
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS ~ Designation enables an enhanced development ...
In a phase 2 trial, intravesical TARA-002 showed a 72% complete response rate at any time among patients with high-grade NMIBC naïve to BCG. The investigational intravesical cell therapy TARA-002 ...
In an exclusive interview with Hypebeast, the designer shares how she turned her hand to transforming her favorite rum bottle.
TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...
The Thor 002 uses a 256 x 192 thermal sensor – its true resolution – and produces a digitally enhanced 512 x 384 image to make thermal maps crisper. Sure, this isn't high-end imaging tech, which you'd ...
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
After all, this lofty third space offers a barbershop, coffee shop, clothing store, restaurant, cocktail lounge, and private dining space, all of it accessed through a minty green entry floor designed ...
Capsida Biotherapeutics paused the SYNRGY trial for CAP-002 after a participant's death, collaborating with the FDA to investigate the cause and ensure patient safety. The CAP-002 trial, targeting ...
Narwal has officially launched the Freo 002 Max robot vacuum cleaner in China. The device features a suction power of up to 25,000Pa, an advanced self-cleaning system, and a new sterilization feature ...
A new immune vaccine has emerged that reduces the risk of recurrence of pancreatic and colorectal cancers and increases the possibility of long-term survival. The U.S. biotechnology corporations ...
Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results